• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

动态对比增强 MRI 用于评估接受新辅助放化疗的食管癌患者的治疗反应。

Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy.

机构信息

Department of Radiotherapy, University Medical Center Utrecht, Netherlands.

Department of Radiotherapy, University Medical Center Utrecht, Netherlands; Department of Surgery, University Medical Center Utrecht, Netherlands.

出版信息

Radiother Oncol. 2016 Jul;120(1):128-35. doi: 10.1016/j.radonc.2016.05.009. Epub 2016 Jun 10.

DOI:10.1016/j.radonc.2016.05.009
PMID:27296409
Abstract

PURPOSE

To explore and evaluate the potential value of dynamic contrast-enhanced (DCE) magnetic resonance imaging (MRI) for the prediction of pathologic response to neoadjuvant chemoradiotherapy (nCRT) in oesophageal cancer.

MATERIAL AND METHODS

Twenty-six patients underwent DCE-MRI before, during (week 2-3) and after nCRT, but before surgery (pre/per/post, respectively). Histopathologic tumour regression grade (TRG) was assessed after oesophagectomy. Tumour area-under-the-concentration time curve (AUC), time-to-peak (TTP) and slope were calculated. The ability of these DCE-parameters to distinguish good responders (GR, TRG 1-2) from poor responders (noGR, TRG⩾3), and pathologic complete responders (pCR) from no-pCR was assessed.

RESULTS

Twelve patients (48%) showed GR of which 8 patients (32%) pCR. Analysis of AUC change throughout treatment, AUCper-pre, was most predictive for GR, at a threshold of 22.7% resulting in a sensitivity of 92%, specificity of 77%, PPV of 79%, and a NPV of 91%. AUCpost-pre was most predictive for pCR, at a threshold of -24.6% resulting in a sensitivity of 83%, specificity of 88%, PPV of 71%, and a NPV of 93%. TTP and slope were not associated with pathologic response.

CONCLUSIONS

This study demonstrates that changes in AUC throughout treatment are promising for prediction of histopathologic response to nCRT for oesophageal cancer.

摘要

目的

探讨和评估动态对比增强(DCE)磁共振成像(MRI)在预测食管癌新辅助放化疗(nCRT)病理反应中的潜在价值。

材料与方法

26 例患者在 nCRT 前(pre)、期间(week 2-3,per)和之后(post)进行 DCE-MRI 检查,但在手术前。在食管癌切除术后评估组织病理学肿瘤消退分级(TRG)。计算肿瘤浓度时间曲线下面积(AUC)、达峰时间(TTP)和斜率。评估这些 DCE 参数区分良好反应者(GR,TRG 1-2)和不良反应者(noGR,TRG≥3)以及病理完全缓解者(pCR)和非 pCR 的能力。

结果

12 例患者(48%)表现为 GR,其中 8 例(32%)为 pCR。分析整个治疗过程中 AUC 的变化(AUCper-pre)对 GR 最具预测性,阈值为 22.7%时,敏感性为 92%,特异性为 77%,阳性预测值为 79%,阴性预测值为 91%。AUCpost-pre 对 pCR 最具预测性,阈值为-24.6%时,敏感性为 83%,特异性为 88%,阳性预测值为 71%,阴性预测值为 93%。TTP 和斜率与病理反应无关。

结论

本研究表明,整个治疗过程中 AUC 的变化对预测食管癌 nCRT 的组织病理学反应具有很大的潜力。

相似文献

1
Dynamic contrast-enhanced MRI for treatment response assessment in patients with oesophageal cancer receiving neoadjuvant chemoradiotherapy.动态对比增强 MRI 用于评估接受新辅助放化疗的食管癌患者的治疗反应。
Radiother Oncol. 2016 Jul;120(1):128-35. doi: 10.1016/j.radonc.2016.05.009. Epub 2016 Jun 10.
2
DW-MRI and DCE-MRI are of complementary value in predicting pathologic response to neoadjuvant chemoradiotherapy for esophageal cancer.DCE-MRI 和 DWI-MRI 在预测食管癌新辅助放化疗病理反应方面具有互补价值。
Acta Oncol. 2018 Sep;57(9):1201-1208. doi: 10.1080/0284186X.2018.1473637. Epub 2018 May 21.
3
Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.扩散加权磁共振成像预测食管癌新辅助放化疗的病理反应
Radiother Oncol. 2015 May;115(2):163-70. doi: 10.1016/j.radonc.2015.04.027. Epub 2015 May 19.
4
Optimal timing for prediction of pathologic complete response to neoadjuvant chemoradiotherapy with diffusion-weighted MRI in patients with esophageal cancer.用扩散加权 MRI 预测食管癌新辅助放化疗病理完全缓解的最佳时机。
Eur Radiol. 2020 Apr;30(4):1896-1907. doi: 10.1007/s00330-019-06513-0. Epub 2019 Dec 10.
5
Preoperative image-guided identification of response to neoadjuvant chemoradiotherapy in esophageal cancer (PRIDE): a multicenter observational study.术前图像引导识别食管癌新辅助放化疗反应(PRIDE):一项多中心观察性研究。
BMC Cancer. 2018 Oct 20;18(1):1006. doi: 10.1186/s12885-018-4892-6.
6
The value of GRASP on DCE-MRI for assessing response to neoadjuvant chemotherapy in patients with esophageal cancer.GRASP 在评估食管癌新辅助化疗反应中的 DCE-MRI 价值。
BMC Cancer. 2019 Oct 24;19(1):999. doi: 10.1186/s12885-019-6247-3.
7
[Application value of texture analysis of magnetic resonance images in prediction of neoadjuvant chemoradiotherapy efficacy for rectal cancer].磁共振图像纹理分析在预测直肠癌新辅助放化疗疗效中的应用价值
Zhonghua Wei Chang Wai Ke Za Zhi. 2018 Sep 25;21(9):1051-1058.
8
Could perfusion heterogeneity at dynamic contrast-enhanced MRI be used to predict rectal cancer sensitivity to chemoradiotherapy?动态对比增强磁共振成像中的灌注异质性能否用于预测直肠癌对放化疗的敏感性?
Clin Radiol. 2018 Oct;73(10):911.e1-911.e7. doi: 10.1016/j.crad.2018.06.007. Epub 2018 Jul 17.
9
Diagnostic performance of MRI for assessment of response to neoadjuvant chemoradiotherapy in oesophageal cancer.MRI 对评估食管癌新辅助放化疗反应的诊断性能。
Br J Surg. 2019 Apr;106(5):596-605. doi: 10.1002/bjs.11094. Epub 2019 Feb 25.
10
Can perfusion MRI predict response to preoperative treatment in rectal cancer?灌注磁共振成像能否预测直肠癌术前治疗的反应?
Radiother Oncol. 2015 Feb;114(2):218-23. doi: 10.1016/j.radonc.2014.11.044. Epub 2014 Dec 10.

引用本文的文献

1
Advancing Esophageal Cancer Staging and Restaging: The Role of MRI in Precision Diagnosis.进展期食管癌的分期与再分期:MRI在精准诊断中的作用
Cancers (Basel). 2025 Apr 17;17(8):1351. doi: 10.3390/cancers17081351.
2
Diagnosing Complete Response to Preoperative Chemoradiation in Esophageal Cancer Using Dynamic Contrast-Enhanced MRI Response Criteria.使用动态对比增强MRI反应标准诊断食管癌术前放化疗的完全缓解
Korean J Radiol. 2025 Mar;26(3):269-280. doi: 10.3348/kjr.2024.0896.
3
Prognostic value of pretreatment radiological MRI variables and dynamic contrast-enhanced MRI on radiotherapy treatment outcome in laryngeal and hypopharyngeal tumors.
治疗前放射学磁共振成像(MRI)变量及动态对比增强MRI对喉癌和下咽癌放射治疗结果的预后价值
Clin Transl Radiat Oncol. 2024 Sep 12;49:100857. doi: 10.1016/j.ctro.2024.100857. eCollection 2024 Nov.
4
Radiomics in Oesogastric Cancer: Staging and Prediction of Preoperative Treatment Response: A Narrative Review and the Results of Personal Experience.食管癌和胃癌中的放射组学:术前治疗反应的分期与预测:一项叙述性综述及个人经验结果
Cancers (Basel). 2024 Jul 26;16(15):2664. doi: 10.3390/cancers16152664.
5
Early Contrast-Enhanced MR for Diagnosing Complete Tumor Response of Locally Advanced Esophageal Squamous Cell Carcinoma After Neoadjuvant Therapy: A Retrospective Comparative Study.早期增强磁共振成像用于诊断新辅助治疗后局部晚期食管鳞癌完全肿瘤缓解的回顾性对比研究。
Ann Surg Oncol. 2024 Jul;31(7):4271-4280. doi: 10.1245/s10434-024-15123-0. Epub 2024 Mar 7.
6
Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy.基线和中期 [18F]FDG-PET/MRI 用于评估接受根治性治疗的 M0 食管鳞癌患者的治疗反应和生存情况。
Cancer Imaging. 2023 Nov 6;23(1):109. doi: 10.1186/s40644-023-00630-2.
7
Radiomics characterization of tissues in an animal brain tumor model imaged using dynamic contrast enhanced (DCE) MRI.利用动态对比增强(DCE)MRI 对动物脑肿瘤模型中的组织进行放射组学特征分析。
Sci Rep. 2023 Jul 2;13(1):10693. doi: 10.1038/s41598-023-37723-8.
8
Dynamic contrast enhanced (DCE) MRI estimation of vascular parameters using knowledge-based adaptive models.基于知识的自适应模型的动态对比增强(DCE)MRI 血管参数估计。
Sci Rep. 2023 Jun 14;13(1):9672. doi: 10.1038/s41598-023-36483-9.
9
The application of radiomics in esophageal cancer: Predicting the response after neoadjuvant therapy.放射组学在食管癌中的应用:预测新辅助治疗后的反应。
Front Oncol. 2023 Apr 6;13:1082960. doi: 10.3389/fonc.2023.1082960. eCollection 2023.
10
Nonoperative management of gastrointestinal malignancies in era of neoadjuvant treatment.新辅助治疗时代胃肠道恶性肿瘤的非手术治疗
Chin J Cancer Res. 2023 Feb 28;35(1):44-57. doi: 10.21147/j.issn.1000-9604.2023.01.05.